What is the recommended approach for investigation and management of acute hepatitis?

Acute Hepatitis Investigation and Management

For acute hepatitis, immediately assess for acute liver failure (ALF) by checking INR and mental status, then conduct a comprehensive etiologic workup including viral serologies (HAV, HBV, HCV, HEV if pregnant), autoimmune markers, drug/toxin history, and HSV testing, while providing supportive care and reserving specific antiviral therapy for acetaminophen toxicity (N-acetylcysteine), severe acute hepatitis B, and HSV hepatitis.

Initial Assessment and Risk Stratification

Determine Disease Severity First

The critical first step is distinguishing between uncomplicated acute hepatitis and acute liver failure, as this fundamentally changes management:

• Check INR and assess for encephalopathy immediately
• ALF is defined by coagulopathy (INR >1.5) plus encephalopathy in a patient without pre-existing cirrhosis 1
• Acute severe presentation without encephalopathy (INR >1.5 but no altered mental status) represents an intermediate category requiring close monitoring 2

If ALF is present, immediately contact a transplant center - mortality without transplantation approaches 70-90% depending on etiology 1.

Diagnostic Workup

Essential Initial Testing

Perform these tests on all patients with acute hepatitis:

Viral serologies:

• Hepatitis A: Anti-HAV IgM
• Hepatitis B: HBsAg, anti-HBc IgM, anti-HBs
• Hepatitis C: Anti-HCV antibody with HCV RNA if positive
• Hepatitis E: HEV testing in pregnant women (mortality up to 25% in this population) 1
• HSV DNA and serologies (HSV causes 1% of ALF cases but is treatable) 1

Autoimmune markers:

• ANA, ASMA, anti-LKM1, anti-LC1
• Serum IgG levels (though 10% of autoimmune hepatitis patients have normal IgG at presentation) 2
• Note: 25-39% of acute autoimmune hepatitis cases have normal IgG, complicating diagnosis 2

Metabolic/toxic screen:

• Comprehensive medication history including herbals, supplements, and recreational drugs
• Acetaminophen level
• Alcohol use assessment
• Ceruloplasmin and 24-hour urinary copper (Wilson's disease - only if high clinical suspicion, as routine testing has low positive predictive value) 1

Testing NOT Routinely Recommended

• Routine liver biopsy in ALF - the AGA suggests against this due to bleeding risk and limited impact on management 1
• Routine VZV testing in immunocompetent patients - only 10 case reports exist, mostly in immunocompromised hosts 1
• Universal Wilson's disease screening - low yield unless specific clinical features present 1

Management Approach

Supportive Care (All Patients)

• High-calorie diet as tolerated
• Avoid hepatotoxic medications
• Absolute alcohol abstinence
• Bedrest if symptomatic
• IV hydration if unable to maintain oral intake
• Stop or change any medication started within 12 months of liver injury 2

Specific Antiviral Therapy

Acetaminophen-associated ALF:

• N-acetylcysteine is strongly recommended - this is the only strong recommendation in ALF management 1
• Start immediately, even if presentation is delayed

Herpes Simplex Virus:

• Treat with acyclovir if HSV DNA positive - poor prognosis even with treatment, but case reports suggest benefit 1
• Low downside to empiric treatment in ALF of unclear etiology

Acute Hepatitis B:

• Most cases resolve spontaneously and do not require treatment 3
• Consider oral antivirals (entecavir or tenofovir) only in severe acute hepatitis B or evolving ALF 4, 3
• Treatment should be started urgently in severe cases to prevent death 4

Acute Hepatitis C:

• Early interferon therapy may reduce chronic infection risk, but no established guidelines exist 5
• Most treatment decisions are individualized

Autoimmune Hepatitis Management

Acute severe autoimmune hepatitis (AS-AIH):

• Defined as acute presentation with jaundice and INR >1.5 but without encephalopathy
• Two-thirds of patients receiving corticosteroids survive without transplantation 2
• Consider steroid trial even if diagnosis uncertain, especially if transaminases don't improve after drug withdrawal 2

AIH with ALF (encephalopathy present):

• Urgent liver transplant evaluation required - steroids show no survival benefit in this setting 2
• Recovery occurs in only 9-32% without transplantation 2

Prognostic Assessment in ALF

Use MELD score rather than King's College Criteria 1:

• MELD ≥30.5 predicts need for liver transplantation
• This is a conditional recommendation based on very low quality evidence

Treatments to AVOID

• Do NOT use empiric intracranial pressure reduction measures in ALF 1
• Do NOT use extracorporeal liver support systems outside clinical trials 1
• Do NOT use N-acetylcysteine for non-acetaminophen ALF outside clinical trials 1

Critical Pitfalls

1. Missing autoimmune hepatitis in acute presentations - normal IgG doesn't exclude the diagnosis 2
2. Delaying transplant evaluation in ALF - contact transplant center immediately when encephalopathy develops
3. Forgetting hepatitis E in pregnant women - this has significant mortality and requires specific testing 1
4. Treating all acute hepatitis B - most cases resolve spontaneously; reserve antivirals for severe disease 3
5. Assuming drug-induced hepatitis will improve with continued exposure - stop suspected medications immediately 2

Follow-up Strategy

• Serial monitoring of INR, transaminases, and bilirubin
• Watch for development of encephalopathy (triggers transplant evaluation)
• Reassess diagnosis if no improvement after drug withdrawal
• Screen family members if Wilson's disease or autoimmune hepatitis diagnosed